| 000 | 01062 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516210855.0 | ||
| 264 | 0 | _c20140604 | |
| 008 | 201406s 0 0 eng d | ||
| 022 | _a1756-1833 | ||
| 024 | 7 |
_a10.1136/bmj.g2779 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMontori, Victor M | |
| 245 | 0 | 0 |
_aThe safety of incretin based drugs. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cApr 2014 |
||
| 300 |
_ag2779 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xanalogs & derivatives |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aIncretins _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPancreatitis _xchemically induced |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 348 _gp. g2779 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.g2779 _zAvailable from publisher's website |
| 999 |
_c23767611 _d23767611 |
||